Showing results (81-90 of 110) with videos related to
Sort By:
Pageof 11
Hemasphere|August 17, 2022
Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular LymphomasHeike Horn, Vindi Jurinovic, Ellen Leich, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C Kluin-Nelemans, Eva Hoster, Olivier Hermine, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized TrialsQian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Linmiao Jiang, Jan Walewski, et al.Annals of Hematology|July 12, 2011
Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)Friederike Schneider, Eva Hoster, Stephanie Schneider, et al.Blood|June 24, 2021
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphomaKai Rejeski, Ariel Perez, Pierre Sesques, et al.Virchows Archiv : an International Journal of Pathology|February 2, 2021
Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic featuresSietse M Aukema, Giorgio A Croci, Susanne Bens, et al.Blood Advances|September 17, 2020
Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk modelsStefan Alig, Vindi Jurinovic, Mohammad Shahrokh Esfahani, et al.Hemasphere|July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product UseVeit Bücklein, Ariel Perez, Kai Rejeski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemiaFriederike Pastore, Annika Dufour, Tobias Benthaus, et al.Pageof 11